CD274 and neoplasm: For example, nanoparticles encapsulating G4 stabilizers can be designed to selectively release drugs at tumor sites, improve pharmacokinetics, and minimize off-target effects These nanocarriers can also be used to co-deliver anti-PD-L1 antibodies to enhance anti-tumor immune responses while modulating G4-related immune pathways.